1VANNUCCHI AM,ANTONIOLI E,GUGLIELMELLI P,et al.Charac-teristics and clinical correlates of MPL515W>L/Kmutation in essen-tial thrombocythemia. Blood . 2008 被引量：1
2JOST E,,do O N,DAHI E,et al.Epigenetic alterations complementmutation of JAK2 tyrosine kinase in patients with BCR/ABL-negativemyeloproliferative disorders. Leukemia . 2007 被引量：1
3LASHO TL,TEFFERI A,HOOD JD,et al.TG101348,a JAK2-selec-tive antagonist,inhibits primary hematopoietic cells derived from my-eloproliferative disorder patients with JAK2V617F,MPLW515K orJAK2 exon 12 mutations as well as mutation negative patients. Leukemia . 2008 被引量：1
4Levine RL,Heaney M.New advances in the pathogeneses and therapy of essential thrombocythemia. Hematology Am Soc Hematol Educ Program . 2008 被引量：1
5Dupont S,Mass A,James C,et al.The JAK2617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood . 2007 被引量：1
6Kiladjian JJ,Cassinat B,Chevret S,et al.Pegylatedinterferon-alfa-2a induces complete hematologic andmolecular responses with low toxicity in polycythemiavera. Blood . 2008 被引量：1
7Pardanani AD,Levine RL,Lasho T,et al.MPL515 mutationsin myeloproliferative and other myeloid disorders:a study of1182 patients. Blood . 2006 被引量：1
8Beer PA,Campbell PJ,Scott LM,et al.MPL mutations in myeloproliferative disorders:analysis of the PT-1 cohort. Blood . 2008 被引量：1
9Kralovics R,Passamonti F,Buser AS,et al.A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine, The . 2005 被引量：1
10Campbell PJ,Scott LM,Buck G,et al.Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet,The . 2005 被引量：1
6Gangat N, Wolanskyj AP, McClure RF, et ai. Risk stratification for survival and leukemic transformation in essentialthrombocythemial a single institutional study of 605 patients. Leukemia, 2007,21 : 1270- 1276. 被引量：1
9Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, 2005 : 48-50. 被引量：1
10Georgii A, Buesche G, Kreft A. The histopathology of chronic myelo- proliferative diseases. Baillieres Clin Haematol, 1998,11:721-749. 被引量：1
